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Abstract
RB1-inducible coiled-coil 1 (RB1CC1) plays a significant role in the enhancement of the retinoblastoma tumor suppressor
(RB1) pathway and is involved in breast cancer development. However, RB1CC1’s role in clinical progression of breast cancer
has not yet been evaluated, so, as a first step, it is necessary to establish its usefulness as a tool to evaluate breast cancer
patients. In this report, we have analyzed the correlation between abnormalities in the RB1CC1 pathway and long-term
prognosis, because disease-specific death in later periods (.5 years) of the disease is a serious problem in breast cancer.
Breast cancer tissues from a large cohort in Japan were evaluated by conventional immunohistochemical methods for the
presence of the molecules involved in the RB1CC1 pathway, including RB1CC1, RB1, p53, and other well-known prognostic
markers for breast cancer, such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor
2. The correlation between the immunohistochemical results and clinical outcomes of 323 breast cancer patients was
analyzed using a Kaplan-Meier log-rank test and a multivariate Cox proportional hazards regression analysis. Absence of
nuclear RB1CC1 expression was associated with the worst prognosis (Log-rank test, Chi-Square value=17.462, p,0.0001).
Dysfunction of either one of RB1CC1, RB1, or p53 was associated with the highest risk for cancer-specific death, especially
related to survival lasting more than 5 years (multivariate Cox proportional hazard ratio=3.951, 95% Confidence
Interval=1.566–9.967, p=0.0036). Our present data demonstrate that the combined evaluation of RB1CC1, RB1 and p53 by
conventional immunohistochemical analysis provides an accurate prediction of the long-term prognoses of breast cancer
patients, which can be carried out as a routine clinical examination.
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Introduction
Conventional prognostic markers of breast cancer, such as age,
tumor-node-metastasis (TNM) stage, and hormone receptor status
are lacking in their ability to predict the recurrence or disease-
specific death in later periods (.5 years) of the disease, which is
one of the greatest problems during the postoperative clinical
follow-up[1]. Clinical assays for estrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth factor receptor
2 (HER2) are useful for choosing the best postoperative adjuvant
therapy. The likelihood of distant recurrence and cancer-specific
death in triple-negative [ER(2), PR(2) and HER2(2)] breast
cancer is larger than that of non-triple-negative cases, and the
maximum difference is observed at 3 years after diagnosis.
Thereafter, the difference between these two groups decreases
year by year up to 10 years[1,2,3]. Therefore, the development of
other diagnostic parameters for the risk of death from cancer in
later periods (.5 years) of the disease is a matter of great interest.
As in many other cancers, the prognosis of breast cancer seems
to be intimately related to its cytogenetic disorders. The
retinoblastoma tumor suppressor (RB1) protein regulates G1/S-
phase cell cycle progression and is a critical mediator of
antiproliferative signaling. RB1 has been reported to be aberrant
in approximately 20% of breast cancer cases[4,5], and to be
associated with a poor disease outcome[5,6]. However, the
regulatory mechanism of RB1 has not been fully clarified yet,
although its function has been shown to be regulated mainly by
phosphorylation[7]. RB1 status has only infrequently been applied
to breast cancer prognostication[6]. RB1-inducible coiled-coil 1
(RB1CC1: the symbol used here is approved by the Human
Genome Organization [HUGO] Gene Nomenclature Committee;
it is also known as FIP200, [focal adhesion kinase family-
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regulator that in particular enhances RB1 transcription[8,9]. A
genetic rearrangement of RB1CC1 has also been suggested to be
involved in the tumorigenesis of breast cancer[9,10]. In addition,
RB1CC1 has been reported to be involved in proliferation[8,11],
growth[12,13], apoptosis[14,15] and autophagy[16,17,18]. Re-
cently, we have demonstrated that nuclear RB1CC1 binds to the
201bp upstream GC-rich region (from the initiation ATG) of the
RB1 promoter and activates RB1 expression[19]. We have also
reported that RB1CC1 forms a complex between p53 and/or
hSNF5 (also known as BAF47 or INI1), acting as a chromatin-
remodeling factor in cell nuclei, and that the complex provides a
strong activation of RB1, p16 and p21 promoters[20]. The
coordinated expressions of RB1, p16 and p21 influence the
proliferation activity in clinical breast cancer. Therefore, the
immunohistochemical status of RB1, p53 and RB1CC1 may
predict tumor progression and the clinical prognosis of breast
cancer patients[20].
Our present study is designed to establish a convenient routine
clinical method to evaluate the influence of abnormalities in this
newly established pathway—i.e. the RB1CC1, p53- RB1 path-
way—on the long-term prognosis of breast cancer.
Results
Loss of nuclear RB1CC1 expression correlates with triple-
negative phenotype of breast cancer
The correlation between nuclear RB1CC1 expression and other
clinical parametersof the expandedcohort wasanalyzed statistically
(Table 1). Loss of nuclear RB1CC1 [RB1CC1(2)] correlated
significantly with negative PR expression (p=0.0003) and with a
triple-negative [ER(2), PR(2) and HER2(2)] phenotype of breast
cancer (p=0.0003). The use of chemotherapy was significantly
higher in RB1CC1(2) patients than in RB1CC1(+) patients
(p,0.0001), and was also higher in patients with triple-negative
cancers than in those with non-triple-negative disease (Chi-square
and Fisher’s exact test, p,0.0001; data not shown).
RB1CC1 is a prognostic predictor in breast cancer
patients
The Kaplan-Meier curve together with a log-rank analysis
showed a significant relationship between nuclear RB1CC1
expression and breast cancer-specific survival (disease-specific
survival: DSS), in which RB1CC1(2) predicted a worse prognosis
for patients than did RB1CC1(+) (Chi-Square value=17.462,
p,0.0001; Fig. 1A). The relative hazards for DSS associated with
15 categorical risk factors were evaluated individually by a Cox
proportional hazards analysis (Table 2). RB1CC1 conferred a
significant relative hazard (p,0.0001) in addition to the risks of
chemotherapy, tumor size, lymph node status, TNM class, ER,
PR, triple-negative cancer, and RB1. Dysfunction of RB1CC1,
RB1 or p53 (abnormal RB1CC1/RB1/p53) had the highest
hazard ratio for DSS (Hazard ratio=7.385, 95% Confidence
Interval=3.116–6.185, p,0.0001; Table 2). We reported earlier
that nuclear RB1CC1 expression was highly correlated with
expressions of RB1[19] and p16[19,20], and that RB1CC1 and
p53 provided a good stimulation of the coordinated expressions of
RB1, p16 and p21, which, in turn, influenced tumor progression.
Therefore, the immunohistochemical status of RB1, p53 and
RB1CC1 might predict the prognosis of clinical breast cancer[20].
Indeed, together with the preliminary data of a small cohort (Fig.
S1), these data suggested that the combined evaluation of RB1,
RB1CC1, and p53 might provide useful information as prognostic
biomarkers.
Table 1. Patient and tumor characteristics stratified by
nuclear RB1CC1 expression.
Feature Number Nuclear RB1CC1 p-Value
negative (%) positive (%)
Menopause 0.1204
Pre- 142 37 (37) 105 (47)
Post- 182 62 (62) 120 (53)
anti-Estrogen therapy 0.0540
none 85 33 (33) 52 (23)
performed 239 66 (67) 173 (77)
Chemotherapy ,0.0001
none 179 33 (33) 146 (65)
performed 145 66 (67) 79 (35)
Radiation 0.1248
none 108 27 (27) 81 (36)
performed 216 72 (73) 144 (64)
T grade: tumor size 0.0805
#T1 138 35 (35) 103 (46)
T2# 186 64 (65) 122 (54)
Nodes 0.0567
negative 210 56 (58) 154 (69)
positive 111 41 (43) 70 (31)
Stage: TNM class 0.2605
#IIA 228 64 (67) 164 (73)
IIB# 93 32 (33) 61 (27)
ER 0.0689
positive 188 50 (51) 138 (61)
negative 136 49 (49) 87 (39)
PR 0.0003
positive 170 37 (37) 133 (59)
negative 154 62 (63) 92 (41)
HER2 0.1553
negative 290 85 (86) 205 (91)
positive 34 14 (14) 20 (9)
Triple Negative 0.0003
others 237 59 (60) 178 (79)
triple negative 87 40 (40) 47 (21)
p53 0.3200
normal 244 71 (72) 173 (77)
abnormal 80 28 (28) 52 (23)
RB1 0.0833
positive 308 91 (92) 217 (96)
negative 16 8 (8) 8 (4)
RB1CC1 ------
positive 225 0 (0) 225 (100)
negative 99 99 (100) 0 (0)
RB1CC1/RB1/p53 ------
normal 169 0 (0) 169 (75)
abnormal 155 99 (100) 56 (25)
Chi-square and Fisher’s exact tests was used to evaluate the relationships
between clinical parameters and nuclear RB1CC1 expression. p-value ,0.05,
statistically significant.
doi:10.1371/journal.pone.0015737.t001
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provides the most significant prognostic prediction in
Japanese breast cancer patients
To confirm the status of RB1, RB1CC1 and p53 as prognostic
indicators of breast cancer, their expressions in breast cancer tissues
of a larger cohort of 323 Japanese patients were immunohisto-
chemically evaluated, and the correlation with the clinical data was
analyzed statistically. Sixteen cases lacking RB1 expression had
poor prognosis (Table 2; Fig. S2). RB1CC1 (2) status and p53ab
were present in 99 and 80 cases, respectively, in this larger cohort.
RB1CC1 (2) status was associated withthe worst prognosis for DSS
in this series (Log-rank test; Chi-Square value=17.462, p,0.0001;
Fig. 1A), quite similar to the results associated with RB1 (2) cases.
p53 status alone had no statistically significant correlation with DSS
(Log-rank test; Chi-Square value=3.059, p=0.0803; Fig. 1B). It is
important to note that the prognosis of 168 cases without any deficit
in RB1CC1/RB1/p53 immunoreactivity was significantly better
than that of 155 cases with deficits in any one of these three
components (Log-rank test; Chi-Square value=28.496, p,0.0001),
and that very few increments in breast cancer-specific death in the
former group occurred even after five years from clinical disease
onset (Fig. 1C). In this series, DSS of triple-negative breast cancers
became distinctly worse than that of the remaining cases year by
year for 3–5 years (Log-rank test; Chi-Square value=25.279,
p,0.0001), but the difference gradually decreased thereafter
(Fig. 1D). A multivariate Cox proportional hazards analysis showed
that RB1CC1 (2) status was a statistically significant risk for DSS
(Hazard ratio=2.037, p=0.0310) in addition to the risks of triple-
negative, TNM high-class, and chemotherapy-performed status
(Fig. S3A). More important, dysfunction of either one of RB1CC1,
RB1, or p53 was associated with the highest risk for disease-specific
death (Multivariate Cox proportional hazards ratio=3.951,
95% Confidence Interval=1.566–9.967, p=0.0036; Table 3). In
addition, the combined evaluation of RB1CC1, RB1, and p53
predicted a longer DSS in the 236 cases with non-triple-negative
cancers (Log-rank test, Chi-Square value=18.543, p,0.0001;
Fig. 2); i.e., no cancer-specific deaths were recorded among
RB1CC1(+)/RB1(+)/p53nor patients at the follow-up after more
than 5 years. With regard to disease-free survival (DFS), RB1CC1
was a risk factor (Log-rank test, Chi-Square value=13.419,
p=0.0002; Fig. S4A). The combined evaluation of RB1CC1,
RB1 and p53 also provided more accurate information than simple
evaluationofp53ortriple-negativity[ER(2),PR(2)andHER2(2)]
(Log-ranktest, Chi-Squarevalue=19.295,p,0.0001; Fig.S4A–D).
However, a multivariate Cox proportional hazards analysis
indicated that DFS risk was not associated with the status of
RB1CC1/RB1/p53 or triple-negativity, but with TNM high-class
and chemotherapy-performed status (Fig. S4E).
Figure 1. RB1CC1 is a novel prognostic factor in human breast cancer. Three hundred twenty-three cases of breast cancer were
immunohistochemically evaluated and statistically analyzed relative to the clinical outcomes. Kaplan-Meier survival curves with Log-rank tests were
performed for DSS evaluation of (A) RB1CC1, (B) p53, (C) the combination of RB1CC1/RB1/p53, and (D) triple-negative for ER/PR/HER2.
doi:10.1371/journal.pone.0015737.g001
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Nuclear expression of RB1CC1 could be important for tumor
suppression. As reported previously, RB1CC1 is located not only in the
nuclei but also in the cytoplasm[11,16,18,19]. Cytoplasmic RB1CC1
has been suggested as a possible equivalent of yeast Atg17, and several
studies have indicated that RB1CC1 functions as an essential molecule
in autophagy regulation[16,17,18]. Autophagy has been implicated in
tumorigenesis[21,22], but its precise role is ambiguous[23]. It is
conceivable that autophagy has different roles in the different stages, or
contexts, of tumorigenesis[23,24,25,26,27]. Young, et al.[28] have
reported that autophagy mediates the mitotic senescence, an early
window into tumor development. We suggest that cytoplasmic-nuclear
transition of RB1CC1 plays a key role in the autophagy-senescence
association. Cytoplasmic RB1CC1 seems to play no role as a direct
tumor suppressor[20]. In fact, Martin, et al.[29] have reported that
PIASy (a protein-inhibitor of activated STAT protein y) interacts with
RB1CC1 and recruits an interacting complex between PIASy and
RB1CC1 from cytoplasm into nuclei. In nuclei, PIASy positively
activates the p53-p21 signaling pathway together with nuclear
RB1CC1. Our recent data[20] demonstrated that nuclear RB1CC1
forms a large transcriptional complex with hSNF5, p53 and/or PIASy
that activates a global transcription of genes (RB1, p16 and p21)
involved in the RB1 pathway—indicating a possible linkage to mitotic
senescence—and suppresses tumor cell growth. Therefore, a positive
status of nuclear RB1CC1 expression [RB1CC1(+)] appears to be
intimately related to tumor suppression in breast cancer.
Evaluations of ER, PR, and HER2 in tumor tissue are useful for
predicting the potential outcome of postoperative adjuvant therapy of
breast cancer; thus it was demonstrated that patients with triple-
negative cancers had an obviously worse outcome than non-triple-
negative cases during shorter follow-up periods of up to 3–5
years[1,2,3]. However, the ability of triple-negative status to predict
the prognosis diminished considerably after more than 5 years, and had
disappeared at 10 years[1,2,3], so another diagnostic tool to predict the
prognosis, especially related to DSS lasting more than 5 years, is
needed. RB1CC1 is a novel regulator of RB1 that dephosphorylates
RB1[8,11] and increases its expression[8,9,19]. In addition, the
RB1CC1-RB pathway plays an important role in the proliferation of
breast cancer cells in vitro[20], and its genetic rearrangement has been
demonstrated in breast cancer tissue in vivo[9,10]. Accordingly,
RB1CC1 itself and/or molecules (such as p53, SNF5 and PIASy)
involved in the RB1CC1-RB1 pathways may be effective biomarkers
to evaluate the clinical status of breast cancer patients.
In this report, using the hospital-based cohort of 323 breast cancer
cases in Japan, we have shown that RB1CC1 status predicts breast
cancer-specific survival (DSS). It is important to note that other
established risk factors, such as chemotherapy, tumor size, lymph
node status, TNM classification, ER, PR, triple-negative phenotype,
and RB1 also conferred significant univariate relative hazards for
DSS, thus confirming that the present cohort was a representative
population. This population was not selected for RB1CC1status, and




ratio (95% CI) p-Value
Menopause
Pre- 142 (44) 1.000
Post- 181 (56) 0.871 (0.479–1.584) 0.6506
anti-Estrogen therapy
none 85 (26) 1.000
performed 238 (74) 0.920 (0.472–1.792) 0.8063
Chemotherapy
none 179 (55) 1.000




none 108 (33) 1.000
performed 215 (67) 0.571 (0.313–1.044) 0.0685
T grade: tumor size
#T1 138 (43) 1.000
T2# 185 (57) 4.167 (1.855–9.346) 0.0005
Nodes
negative 210 (66) 1.000
positive 110 (34) 4.082 (1.980–6.993) ,0.0001
Stage: TNM class
#IIA 228 (71) 1.000
IIB# 92 (29) 3.704 (2.008–6.803) ,0.0001
ER
positive 187 (58) 1.000
negative 136 (42) 3.206 (1.694–6.070) 0.0003
PR
positive 170 (53) 1.000




negative 290 (90) 1.000
positive 33 (10) 2.151 (0.997–4.630) 0.0507
Triple Negative
others 236 (73) 1.000
triple negative 87 (27) 4.149 (2.271–7.579) ,0.0001
p53
normal 243 (75) 1.000
abnormal 80 (25) 1.737 (0.928–3.254) 0.0843
RB1
positive 307 (95) 1.000




positive 224 (69) 1.000
negative 99 (31) 3.373 (1.840–6.185) ,0.0001
RB1CC1/RB1/p53
normal 168 (52) 1.000
Features Number (%)
hazard
ratio (95% CI) p-Value
abnormal 155 (48) 7.385 (3.116–6.185) ,0.0001
The Cox proportional hazard regression model was used to evaluate the effects
of clinico- pathological parameters on disease-specific-survival (DSS) with 95%
confidence interval (95% CI). p-value ,0.05, statistically significant. DSS
intervals were used as the indicator for the relative-hazards.
doi:10.1371/journal.pone.0015737.t002
Table 2. Cont.
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prognostic factor. In this cohort, RB1CC1(2) status correlated
significantly with PR-negative and triple-negative phenotypes, as well
as chemotherapy, and these findings seem to be closely related
because chemotherapy was often applied to the PR-negative and/or
triple-negative breast cancer patients.
In this cohort, the combined evaluation of RB1CC1, RB1 and
p53 predicted prognoses more accurately than that of nuclear
RB1CC1 expression, especially related to DSS for more than 5
years. In this series, similar to the results found in previous
reports[1,2,3,30,31], patients with non-triple-negative breast
cancers had distinctly better survivals than did those with triple-
negative cancers, but the difference between triple-negative and
non-triple-negative cancers decreased at the longer follow-up. The
disease-specific death of non-triple-negative breast cancer patients
in later follow-up periods (.5 years) is one of the greatest clinical
problems. The combined evaluation of RB1CC1, RB1 and p53
predicted a longer DSS after more than 5 years in the cases with
non-triple-negative cancers; i.e., no cancer-specific death was
recorded among RB1CC1(+)/RB1(+)/p53nor patients in the later
follow-up periods (.5 years). This combined evaluation of
RB1CC1/RB1/p53 can provide a benefit for the clinical manage-
ment of breast cancer patients, and improve upon the individual
evaluations of RB1, p53 or triple-negativity [ER(2), PR(2) and
HER2(2)] to predict the long-term prognosis of breast cancer
patients[1,2,3,6,30,31,32,33]. Although precise genetic analyses of
RB1CC1, RB1 and p53 may offer better information on the
prognosis, these analyses are not widely available as routine
clinical examinations because of the cumbersome and expensive
methodologies involved. The immunohistochemical technique
used in the present study provides a suitable performance with
regard to time and cost, and sufficient accuracy for the clinical
prediction of survival, especially for the longer DSS. This
technique will also provide a way to keep each breast cancer
patient under suitable medical surveillance for specific periods.
Taken together, we have established RB1CC1 as a novel
prognostic predictor in a cohort of Japanese breast cancer patients.
Further studies of larger population cohorts (with more than 1,000
patients and of different races) are expected to confirm the validity
of the RB1CC1/RB1/p53 combination in predicting long-term
prognoses of breast cancer patients.
Materials and Methods
Patients and histology
In the preliminary study, a small cohort of 58 breast cancer cases
treated at Shiga University of Medical Science in 1999 was
analyzed. Absence of nuclear RB1CC1 expression [RB1CC1 (2)]
was associated with the worst prognosis for breast cancer-specific
survival (DSS; Log-rank test, Chi-Square value=11.151,
p=0.0008; Fig. S1A). In addition, cases with any dysfunction in
RB1CC1/RB1/p53 had a DSS prognosis significantly worse than
those without any deficit in these three components (Log-rank test;
Chi-Square value=13.699, p=0.0002; Fig. S1B). These data
suggest that the prognoses of breast cancer patients are predictable
by the immunohistochemical status of RB1CC1, RB1 and p53 in
the primary tumor specimens. Therefore, we analyzed the
correlation between prognosis and the immunohistochemical
findings of the molecules involved in the RB1CC1-RB pathway in
a total of 381 consecutive patients with operable primary breast
cancers treated at Shiga University of Medical Science (72 cases), or
at Osaka Medical Center for Cancer and Cardiovascular Diseases
(309 cases) between 1999 and 2000. Among these cases, we failed to
perform immunohistochemical evaluations in 57 tumor specimens
as a result of tissue loss during slide preparation. Specimens from
324 patients with operable primary breast cancer in the cohort were
immunohistochemically evaluated, but post-operative clinical data
were not available in one case. Therefore, 323 cases were available
for the statistical analysis of immunohistochemical and clinical data
in this study. Data were collected from clinical and pathological
records with the written informed consent of patients and after
approval by the Ethics Committee of each institution; Shiga
University of Medical Science and Osaka Medical Center for
Cancer and Cardiovascular Diseases. The pathological diagnoses of
all the specimens were confirmed by at least two surgical
pathologists (Y.T. and H.O.), and classified according to the World
Health Organization (WHO) guidelines. In the present cohort, the
mean follow-up period was 78.4 months (standard error =1.70
months; range 3–134 months). The mean age at diagnosis was 53.4
years (standard error =0.65 years; range 26–90 years).
Antibodies and reagents
Rabbit antisera against RB1CC1 (aa. 25–271, 549–817 as each
epitope) were generated as previously reported[13,19], and the
Table 3. Multivariate Cox proportional hazards analysis for




ratio (95% CI) p -values
RB1CC1/RB1/p53 IHC (normal vs
abnormal)
3.951 1.566–9.967 0.0036
Subtype ER/PR/HER2 (others vs
triple negative)
1.974 1.038–3.754 0.0382




The Cox’s model was used to evaluate any independent prognostic effect of the
variables on disease-specific survival (DSS) with a 95% confidence interval (95%
CI). p-value ,0.05, statistically significant. DSS intervals were used as the
indicator for the relative-hazards.
doi:10.1371/journal.pone.0015737.t003
Figure 2. The combined evaluation of RB1CC1, RB1 and p53
provide a significant prediction of prognoses in non-triple-
negative breast cancers. Kaplan-Meier method with a log-rank test
was performed in 236 patients with non-triple-negative breast cancers
(Chi-Square value=18.543, p,0.0001).
doi:10.1371/journal.pone.0015737.g002
RB1CC1 Correlates with Breast Cancer Survival
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p21 (F-5) were obtained from Santa Cruz Biotechnology (CA).
Anti-p53 (DO-7), ER (1D5) and PR (PgR636) were purchased
from Sigma (MO). Anti-HER2 (HercepTest) was from DAKO
(Denmark). Anti-RB1 (G3–245) was from BD Biosciences (CA).
Immunohistochemistry
Surgical specimens were transferred to 10% buffered formalin
and fixed overnight. The fixed samples were embedded in paraffin
and serially sliced into 5-mm sections. To evaluate RB1CC1, RB1,
p53, p21, ER, PR and HER2 in human breast cancer tissues,
deparaffinized sections were autoclaved at 120uC for 1 min,
immersed in 0.3% H2O2 and rinsed with 1xPBS before incubation
overnight at 4uC with each of the primary antibodies. The sections
were rinsed with 1xPBS and incubated with the secondary antibody
(Simple Stain MAX-PO; Nichirei, Japan) at room temperature for
1 hour. The sections were then stained with 3,39-diaminobenzidine
tetrahydrochloride (DAB), and counter-stained with hematoxylin.
Microscopic evaluation and statistical analysis for clinical
outcomes
The immunohistochemical results for RB1CC1 were first
quantitatively graded as follows: I, negative stain in both cytoplasm
and nuclei; II, positive stain only in cytoplasm and negative in
nuclei;III,positivestain innucleiwith orwithout stain incytoplasm.
Our recent study proved that RB1 expression was significantly
higher in cases with nuclear RB1CC1 expression (grade III) than in
cases without nuclear RB1CC1 (grade I and II)[19]. In addition, we
have found that nuclear RB1CC1 complexed with p53 and hSNF5
played a functional transcriptional role in the RB1 pathway and
suppressed tumor cell growth[20]. Therefore, in the analysis of the
present clinical cohort, RB1CC1 staining grades I-II and III were
defined as -negative (2) and -positive (+), respectively; i.e., only the
cases with nuclear RB1CC1 expression were recognized as
RB1CC1 (+). A dysfunctional status of p53 was assessed
immunohistochemically by the percentage of cells that were positive
for p53 and p21. Similar to the assignments in the previous
report[20], an abnormal p53 status (p53ab) was defined as a case of
breast cancer if more than 50% of tumor cells were strongly positive
for p53, while less than 10% of the cells were positive for p21. Cells
were considered positive for ER and PR when more than 10% of
the cells stained positive. According to the criteria of the American Cancer
Association, HER2 expression was scored from 0 to 3+,a n da3 +
score was defined as HER2-positive.
Disease-specific survival (DSS: breast cancer-specific survival)
interval was defined by the period from clinical onset to death due
to breast cancer, and disease-free survival (DFS) was the period
until reappearance of breast cancer-related adverse events (i.e.,
breast cancer recurrence or distant metastasis). Statistical analysis
was performed in StatView 5.0 for Windows (StatView Inc., NC).
All tests for statistical significance were two-sided. A p-value of
,0.05 was considered statistically significant. Bivariate analyses of
the association between covariables and RB1CC1 status included
Chi-square and Fisher’s exact tests. Survival curves were estimated
by the Kaplan-Meier method with a log-rank test and the Chi-
square test to assess significance. The univariate and multivariate
Cox proportional hazards regression models were used to evaluate
any independent prognostic effect of the variables with a 95%
confidence interval.
Supporting Information
Figure S1 RB1CC1 is a predictive biomarker for breast cancer
patients. In the preliminary cohort of 58 breast cancer cases,
Kaplan-Meier survival curves with Log-rank tests indicated that
(A) RB1CC1 was a significant predictor for disease-specific
survival (DSS; Log-rank test, Chi-Square value=11.151, p=
0.0008). (B) The combined evaluation of RB1CC1, RB1 and p53
was significantly correlated with DSS (Log-rank test, Chi-Square
value=13.699, p=0.0002).
(TIF)
Figure S2 Sixteen cases lacking RB1 expression had poor
prognosis. Kaplan-Meier survival curves were constructed from 16
cases with RB1-null status in the larger cohort of 324 breast cancer
cases. (A) Disease-specific survival (DSS). (B) Disease-free survival
(DFS).
(TIF)
Figure S3 RB1CC1 is an independent prognostic biomarker for
DSS of breast cancer patients. (A) Multivariate Cox proportional
hazards analysis showed that RB1CC1 (2) was a statistically
significant risk for breast cancer-specific death (Hazard ratio=
2.037, 95% Confidence Interval=1.067–3.887, p=0.0310) in
addition to the risks of triple-negative, TNM high-class, and
chemotherapy-performed status in the 323 breast cancer patient
cohort. (B) Multivariate Cox proportional hazards analysis for
DFS in the cohort.
(TIF)
Figure S4 RB1CC1, RB1 and p53 status predicts clinical
outcomes in cases of breast cancer. Kaplan-Meier survival curves
with Log-rank tests were performed for DFS evaluation of (A)
RB1CC1, (B) p53, (C) the combination of RB1CC1/RB1/p53,
and (D) triple-negative for ER/PR/HER2. (E) Multivariate Cox
proportional hazards analysis indicated that DFS risk was not
associated with the status of RB1CC1/RB1/p53 or triple-
negative, but with TNM high-class and chemotherapy-performed
in the 323 Japanese breast cancer patient cohort.
(TIF)
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